Phase II trial of rituximab-ABVD [doxorubicin + bleomycin + vinblastine + dacarbazine] for classical Hodgkin's disease

Trial Profile

Phase II trial of rituximab-ABVD [doxorubicin + bleomycin + vinblastine + dacarbazine] for classical Hodgkin's disease

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2015

At a glance

  • Drugs Rituximab (Primary) ; Bleomycin; Dacarbazine; Doxorubicin; Vinblastine
  • Indications Hodgkin's disease
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 02 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Apr 2013 Planned end date changed from 1 May 2009 to 1 May 2014 as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top